Effect of Metoclopramide on the Duration of Labor in Women Giving Birth in Kisangani, Democratic Republic of the Congo

Effect of intravenous metoclopramide on the duration of the active phase of labor among women in Kisangani, Democratic Republic of the Congo: a multicenter, randomized, placebo-controlled, single-blind Phase IV clinical trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202608867843382

Enrollment

140

Registered

2026-08-20

Start date

2026-07-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth

Interventions

Sodium chloride injection

Metoclopramide

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women fulfilling all of the following: • age =18 years (or according to local ethical approval) • singleton pregnancy • gestational age between 37+0 and 41+6 weeks • cephalic presentation • spontaneous labor • cervical dilatation exactly 5 cm • reassuring fetal heart rate • intact or ruptured membranes without evidence of chorioamnionitis • eligible for vaginal delivery • written informed consent

Exclusion criteria

Exclusion criteria: • contraindication to vaginal birth • cervical dilatation >5 cm • hypersensitivity to metoclopramide • epilepsy or history of seizures • Parkinson disease • previous extrapyramidal reaction • pheochromocytoma • bowel obstruction or perforation • refusal to participate

Design outcomes

Primary

Measure	Time frame
Duration of the active phase of labor (minutes)	—

Secondary

Measure	Time frame
Need for oxytocin augmentation during labor.;Proportion of participants delivering by spontaneous vaginal delivery, operative vaginal delivery, or cesarean delivery.;Proportion of participants undergoing cesarean delivery because of labor dystocia or failure of labor progression;Number and proportion of participants experiencing adverse events following administration of the study intervention, including somnolence, headache, agitation, extrapyramidal symptoms, allergic reactions, or other clinically identified adverse events;Apgar score assessed using the standard 0-to-10 scale.	—

Measure

Time frame

Need for oxytocin augmentation during labor.;Proportion of participants delivering by spontaneous vaginal delivery, operative vaginal delivery, or cesarean delivery.;Proportion of participants undergoing cesarean delivery because of labor dystocia or failure of labor progression;Number and proportion of participants experiencing adverse events following administration of the study intervention, including somnolence, headache, agitation, extrapyramidal symptoms, allergic reactions, or other clinically identified adverse events;Apgar score assessed using the standard 0-to-10 scale.

—

Countries

Democratic Republic of the Congo

Contacts

Public ContactGEDEON KATENGA

CHEF DE DEPARTEMENT DE GYNECOLOGIE OBSTETRIQUE

jdidier.bosenge@unikis.ac.cd+243823551472

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026